[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350597-105":59,"doc-detail-350597-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","genomic-landscape-of-gnaq-and-gna11-mutations-in-metastatic-solid-tumors-a-real-world-data-analysis","Genomic Landscape of GNAQ and GNA11 Mutations in Metastatic Solid Tumors - A Real-World Data Analysis","","Activating GNAQ and GNA11 mutations function as oncogenic drivers in uveal melanoma, yet their prevalence and genomic context across metastatic solid tumors remained unclear. A pan-cancer next-generation sequencing analysis of 5,416 patients evaluated mutation distribution, hotspot patterns, tumor mutational burden, microsatellite instability, and co-alterations. GNAQ/11 mutations occurred in 0.48%, with a distinct immunogenic subgroup enriched for nonhotspot variants linked to high TMB/MSI. Exploratory outcomes suggested favorable OS with durable ICI benefit.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/genomic-landscape-of-gnaq-and-gna11-mutations-in-metastatic-solid-tumors-a-real-world-data-analysis/350597/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/genomic-landscape-of-gnaq-and-gna11-mutations-in-metastatic-solid-tumors-a-real-world-data-analysis/350597.png","ImageObject",300,407,{"name":92,"@type":93},"Fans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the purpose of this real-world analysis of GNAQ/11 mutations?","Question",{"text":113,"@type":114},"To characterize the genomic landscape of activating GNAQ and GNA11 mutations across metastatic solid tumors, including prevalence and genomic context.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was the study conducted and what data types were assessed?",{"text":118,"@type":114},"It included a pan-cancer cohort of 5,416 metastatic solid tumor patients who underwent next-generation sequencing, assessing mutational distribution, hotspots, TMB, MSI, and co-alterations.",{"name":120,"@type":111,"acceptedAnswer":121},"What distinguishes the immunogenic subgroup identified in the results?",{"text":122,"@type":114},"It showed a strong association with nonhotspot mutations and high TMB/MSI status, and exploratory analysis suggested favorable overall survival with durable immune checkpoint inhibitor benefit.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},350597,1790144078,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},5909892330395,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Original Reports | Biomarkers  \nGenomic Landscape of GNAQ and GNA11 Mutations in Metastatic Solid Tumors: A Real-World Data Analysis  \nMinsuk Kwon, MD, PhD1  ; Yunjin Go, MS2  ; Ji Eun Shin, MD, PhD1  ; Sung Hee Lim, MD, PhD1  ; Jung Yong Hong, MD, PhD1  ; Se Hoon Park, MD, PhD1 ; Joon Oh Park, MD, PhD1  ; Young Suk Park, MD, PhD1  ; Kee-Taek Jang, MD, PhD3  ; Jeeyun Lee, MD, PhD1,2 ; and Seung Tae Kim, MD, PhD1,2   \nDOI [https://doi.org/10.1200/PO-26-00072](https://doi.org/10.1200/PO-26-00072)  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | Activating mutations in GNAQ and GNA11 are recognized oncogenic drivers inuveal melanoma (UM); however, their prevalence across various cancers and their genomic context remain inadequately characterized. This study aimed to elucidate the genomic landscape of these mutations across a range of metastatic solid tumors. |\n| MATERIALS\u003Cbr>AND METHODS | We conducted a pan-cancer analysis involving 5,416 patients with metastatic solid tumors who had undergone next-generation sequencing. Our evaluation encompassed mutational distribution, hotspot identiﬁcation, tumor mutational burden (TMB), microsatellite instability (MSI), and coalterations. |\n| RESULTS | Mutations in GNAQ (n 5 10) or GNA11 (n 5 16) were detected in 26 patients (0.48%). Aside from UM, these mutations were most frequently observed in colorectal cancer (38.5%), melanoma (15.4%), gastric cancer (11.5%), and neuroendocrine tumors (7 . 7%) . A notable subset exhibited an immunogenic proﬁle, with 42.3% classiﬁed as TMB-High (≥10 Mut/Mb) and 19.2% as MSI-High. This immunogenic subgroup was primarily associated with nonhotspot mutations (eg, p.Gln88His, p.Ala231Val), suggesting that these may represent bystander events in hypermutated tumors. Conversely, canonical hotspots (Q209, R183) were predominantly identiﬁed in TMB-Low/ microsatellite stable tumors, such as UM. Notable coalterations included NOTCH3 (80%), FAT1 (70%), and TP53 (37.5%-40%) . Exploratory survival analysis suggested favorable OS in the immunogenic subgroup, supported by cases with durable ICI beneﬁt including a treatment-free remission exceeding 21 months. |\n| CONCLUSION | This real-world analysis demonstrates that GNAQ and GNA11 mutations are not exclusive to UM, occurring across diverse solid tumors, particularly colorectal cancer. The strong association between nonhotspot mutations and high TMB/MSI status deﬁnes a distinct immunogenic subgroup, underscoring the need to differentiate canonical hotspot drivers from bystander mutations when selecting targeted pathway inhibitors versus immune checkpoint blockade. |\n\nACCOMPANYING CONTENT  \n Appendix  \nAccepted May 26, 2026 Published July 6, 2026  \nJCO Precis Oncol 10:e2600072 © 2026 by American Society of Clinical Oncology  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nINTRODUCTION  \nThe guanine nucleotide-binding protein G(q) subunit alpha (GNAQ) and guanine nucleotide-binding protein G(11) subunit alpha (GNA11) are highly homologous paralogs that encode the Gaq and Ga11 proteins, respectively. These proteins serve as critical signaling nodes, acting as alpha subunits of heterotrimeric G-proteins.1 Canonically, activating mutations in GNAQ and GNA11 , predominantly occurring at the Q209 and R183 hotspots, result in the  \nconstitutive activation of downstream signaling pathways. This activation primarily occurs through the phospholipase C/protein kinase C (PKC) axis2 but also involves the engagement of the Hippo pathway effector YAP,3 thereby facilitating oncogenesis.  \nHistorically, these mutations have been most prominently linked to uveal melanoma (UM), where they are regarded as founder events, present in over 80% of cases.4,5 This high prevalence has characterized UM as a distinct molecular  \n[ascopubs.org/journal/po](ascopubs.org/journal/po | 1)[ |](ascopubs.org/journal/po | 1)[ 1](ascopubs.org/journal/po | 1)  \nKwon et al  \nCONTEXT  \nKey Objective  \nWhat are the genomic contexts and immun","cbCaijcxWJaFQLdZ","https://ap.wps.com/l/cbCaijcxWJaFQLdZ","pdf",2445674,13,"English","# Abstract\n## Purpose\n## Materials and Methods\n## Results\n## Conclusion\n# Introduction\n# Context\n## Key Objective\n## Knowledge Generated\n## Relevance","[{\"question\":\"What was the purpose of this real-world analysis of GNAQ/11 mutations?\",\"answer\":\"To characterize the genomic landscape of activating GNAQ and GNA11 mutations across metastatic solid tumors, including prevalence and genomic context.\"},{\"question\":\"How was the study conducted and what data types were assessed?\",\"answer\":\"It included a pan-cancer cohort of 5,416 metastatic solid tumor patients who underwent next-generation sequencing, assessing mutational distribution, hotspots, TMB, MSI, and co-alterations.\"},{\"question\":\"What distinguishes the immunogenic subgroup identified in the results?\",\"answer\":\"It showed a strong association with nonhotspot mutations and high TMB/MSI status, and exploratory analysis suggested favorable overall survival with durable immune checkpoint inhibitor benefit.\"}]","Genomic Landscape of GNAQ and GNA11 Mutations in Metastatic Solid Tumors - A Real-World Data Analysis | PDF",1790089810,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d8fd658c8dde22d497399d19ae3dbe02.webp",983,1315,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa5f1eea9f675592758411ad35f58add.webp",982,1314,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/36b9e11db9f575aa25d57088804c3bd8.webp",981,1312,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/85ee07a1b4edb9bce46f7b7db14d2e38.webp",980,1311]